Fibrocytes represent a novel MDSC subset circulating in patients with metastatic cancer

Blood

Volumn 122, Issue 7, 2013, Pages 1105-1113

  Zhang, Hua ^a   Maric, Irena ^b   DiPrima, Michael J ^a   Khan, Javed ^a   Orentas, Rimas J ^a   Kaplan, Rosandra N ^a   Mackall, Crystal L ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD11B ANTIGEN; CD4 ANTIGEN; COLLAGEN TYPE 1; COLLAGEN TYPE 5; HLA DR ANTIGEN; INDOLEAMINE OXIDASE; INTERLEUKIN 4; OXIDOREDUCTASE; RNA; SMOOTH MUSCLE ACTIN; TRANSCRIPTION FACTOR GATA 3; UNCLASSIFIED DRUG; CD14 ANTIGEN; GATA3 PROTEIN, HUMAN; MESSENGER RNA; TUMOR MARKER;

ADOLESCENT; ADULT; ANGIOGENESIS; ANTIGEN PRESENTATION; ARTICLE; BONE MARROW CELL; CELL DIFFERENTIATION; CELL EXPANSION; CELL FRACTIONATION; CELL SURFACE; CHILD; CONTROLLED STUDY; FIBROBLAST; FIBROCYTE; HUMAN; HUMAN CELL; IMMUNOREACTIVITY; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOCYTE PROLIFERATION; MAJOR CLINICAL STUDY; METASTASIS; MONOCYTE; MYELOID-DERIVED SUPPRESSOR CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; PRIORITY JOURNAL; SARCOMA; T LYMPHOCYTE; BLOOD; CELL CULTURE; CELL PROLIFERATION; DNA MICROARRAY; EWING SARCOMA; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; GENETICS; IMMUNOLOGY; IMMUNOPHENOTYPING; LYMPHOCYTE; LYMPHOCYTE ACTIVATION; METABOLISM; PATHOLOGY; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RHABDOMYOSARCOMA; TH2 CELL; TUMOR ESCAPE; UMBILICAL VEIN ENDOTHELIAL CELL; WESTERN BLOTTING;

ANTIGENS, CD14; BLOTTING, WESTERN; CELL DIFFERENTIATION; CELL PROLIFERATION; CELLS, CULTURED; CHILD; FIBROBLASTS; FLOW CYTOMETRY; GATA3 TRANSCRIPTION FACTOR; GENE EXPRESSION PROFILING; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; IMMUNOPHENOTYPING; IMMUNOSUPPRESSION; INTERLEUKIN-4; LYMPHOCYTE ACTIVATION; LYMPHOCYTES; MONOCYTES; MYELOID CELLS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RHABDOMYOSARCOMA; RNA, MESSENGER; SARCOMA, EWING; TH2 CELLS; TUMOR ESCAPE; TUMOR MARKERS, BIOLOGICAL;

EID: 84887197816     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-08-449413     Document Type: Article

References (53)

1. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science. 2011;331(6024):1565-1570.
2. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol. 2009;9(3):162-174.
3. Serafini P, Borrello I, Bronte V. Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression. Semin Cancer Biol. 2006; 16(1):53-65.
4. Gabrilovich DI, Ostrand-Rosenberg S, Bronte V. Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol. 2012;12(4):253-268.
5. Bronte V, Wang M, Overwijk WW, et al. Apoptotic death of CD81 T lymphocytes after immunization: induction of a suppressive population of Mac-11/Gr-11 cells. J Immunol. 1998; 161(10):5313-5320.
6. Greten TF, Manns MP, Korangy F. Myeloid derived suppressor cells in human diseases. Int Immunopharmacol. 2011;11(7):802-807.
7. Kusmartsev S, Su Z, Heiser A, et al. Reversal of myeloid cell-mediated immunosuppression in patients with metastatic renal cell carcinoma. Clin Cancer Res. 2008;14(24):8270-8278.
8. Diaz-Montero CM, Salem ML, Nishimura MI, Garrett-Mayer E, Cole DJ, Montero AJ. Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol Immunother. 2009;58(1):49-59.
9. Solito S, Falisi E, Diaz-Montero CM, et al. A human promyelocytic-like population is responsible for the immune suppression mediated by myeloid-derived suppressor cells. Blood. 2011; 118(8):2254-2265.
10. Raychaudhuri B, Rayman P, Ireland J, et al. Myeloid-derived suppressor cell accumulation and function in patients with newly diagnosed glioblastoma. Neuro-oncol. 2011;13(6):591-599.
11. Rodriguez PC, Ernstoff MS, Hernandez C, et al. Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes. Cancer Res. 2009; 69(4):1553-1560.
12. Mandruzzato S, Solito S, Falisi E, et al. IL4Ralpha1 myeloid-derived suppressor cell expansion in cancer patients. J Immunol. 2009; 182(10):6562-6568.
13. Vuk-Pavlović S, Bulur PA, Lin Y, et al. Immunosuppressive CD141HLA-DRlow/-monocytes in prostate cancer. Prostate. 2010; 70(4):443-455.
14. Filipazzi P, Valenti R, Huber V, et al. Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colonystimulation factor-based antitumor vaccine. J Clin Oncol. 2007;25(18):2546-2553.
15. Reilkoff RA, Bucala R, Herzog EL. Fibrocytes: emerging effector cells in chronic inflammation. Nat Rev Immunol. 2011;11(6):427-435.
16. Peng H, Herzog EL. Fibrocytes: emerging effector cells in chronic inflammation. Curr Opin Pharmacol. 2012;12(4):491-496.
17. Phillips RJ, Burdick MD, Hong K, et al. Circulating fibrocytes traffic to the lungs in response to CXCL12 and mediate fibrosis. J Clin Invest. 2004; 114(3):438-446.
18. Medbury HJ, Tarran SL, Guiffre AK, et al. Monocytes contribute to the atherosclerotic cap by transformation into fibrocytes. Int Angiol. 2008; 27(2):114-123.
19. Moeller A, Gilpin SE, Ask K, et al. Circulating fibrocytes are an indicator of poor prognosis in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2009;179(7):588-594.
20. Galligan CL, Siminovitch KA, Keystone EC, Bykerk V, Perez OD, Fish EN. Fibrocyte activation in rheumatoid arthritis. Rheumatology (Oxford). 2010;49(4):640-651.
21. Abe R, Donnelly SC, Peng T, Bucala R, Metz CN. Peripheral blood fibrocytes: differentiation pathway and migration to wound sites. J Immunol. 2001;166(12):7556-7562.
22. Pilling D, Buckley CD, Salmon M, Gomer RH. Inhibition of fibrocyte differentiation by serum amyloid P. J Immunol. 2003;171(10):5537-5546.
23. Shao DD, Suresh R, Vakil V, Gomer RH, Pilling D. Pivotal Advance: Th-1 cytokines inhibit, and Th-2 cytokines promote fibrocyte differentiation. J Leukoc Biol. 2008;83(6):1323-1333.
24. Balmelli C, Ruggli N, McCullough K, Summerfield A. Fibrocytes are potent stimulators of anti-virus cytotoxic T cells. J Leukoc Biol. 2005;77(6): 923-933.
25. Chesney J, Bacher M, Bender A, Bucala R. The peripheral blood fibrocyte is a potent antigenpresenting cell capable of priming naive T cells in situ. Proc Natl Acad Sci USA. 1997;94(12): 6307-6312.
26. Curnow SJ, Fairclough M, Schmutz C, et al. Distinct types of fibrocyte can differentiate from mononuclear cells in the presence and absence of serum. PLoS ONE. 2010;5(3):e9730.
27. Balmelli C, Alves MP, Steiner E, et al. Responsiveness of fibrocytes to toll-like receptor danger signals. Immunobiology. 2007;212(9-10): 693-699.
28. Kraman M, Bambrough PJ, Arnold JN, et al. Suppression of antitumor immunity by stromal cells expressing fibroblast activation proteinalpha. Science. 2010;330(6005):827-830.
29. Mackall CL, Rhee EH, Read EJ, et al. A pilot study of consolidative immunotherapy in patients with high-risk pediatric sarcomas. Clin Cancer Res. 2008;14(15):4850-4858.
30. Dagher R, Long LM, Read EJ, et al. Pilot trial of tumor-specific peptide vaccination and continuous infusion interleukin-2 in patients with recurrent Ewing sarcoma and alveolar rhabdomyosarcoma: an inter-institute NIH study. Med Pediatr Oncol. 2002;38(3):158-164.
31. Wong EC, Maher VE, Hines K, et al. Development of a clinical-scale method for generation of dendritic cells from PBMC for use in cancer immunotherapy. Cytotherapy. 2001;3(1):19-29.
32. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001;25(4):402-408.
33. Salvucci O, Maric D, Economopoulou M, Sakakibara S, Merlin S, Follenzi A, Tosato G. EphrinB reverse signaling contributes to endothelial and mural cell assembly into vascular structures. Blood. 2009;114(8):1707-1716.
34. Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledgebased approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA. 2005;102(43):15545-15550.
35. Isakoff MS, Sansam CG, Tamayo P, et al. Inactivation of the Snf5 tumor suppressor stimulates cell cycle progression and cooperates with p53 loss in oncogenic transformation. Proc Natl Acad Sci USA. 2005;102(49):17745-17750.
36. Lindstedt M, Johansson-Lindbom B, Borrebaeck CA. Global reprogramming of dendritic cells in response to a concerted action of inflammatory mediators. Int Immunol. 2002;14(10):1203-1213.
37. Rutella S, Bonanno G, Procoli A, et al. Hepatocyte growth factor favors monocyte differentiation into regulatory interleukin (IL)-1011IL-12low/neg accessory cells with dendritic-cell features. Blood. 2006;108(1):218-227.
38. Pilling D, Fan T, Huang D, Kaul B, Gomer RH. Identification of markers that distinguish monocyte-derived fibrocytes from monocytes, macrophages, and fibroblasts. PLoS ONE. 2009; 4(10):e7475.
39. Hartlapp I, Abe R, Saeed RW, et al. Fibrocytes induce an angiogenic phenotype in cultured endothelial cells and promote angiogenesis in vivo. FASEB J. 2001;15(12):2215-2224.
40. Kao HK, Chen B, Murphy GF, Li Q, Orgill DP, Guo L. Peripheral blood fibrocytes: enhancement of wound healing by cell proliferation, re-epithelialization, contraction, and angiogenesis. Ann Surg. 2011;254(6): 1066-1074.
41. Hou DY, Muller AJ, Sharma MD, et al. Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses. Cancer Res. 2007; 67(2):792-801.
42. Wynn TA. Fibrotic disease and the T(H)1/T(H)2 paradigm. Nat Rev Immunol. 2004;4(8): 583-594.
43. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008; 454(7203):436-444.
44. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet. 2001;357(9255): 539-545.
45. Gabrilovich D. Mechanisms and functional significance of tumour-induced dendritic-cell defects. Nat Rev Immunol. 2004;4(12):941-952.
46. Sica A, Mantovani A. Macrophage plasticity and polarization: in vivo veritas. J Clin Invest. 2012; 122(3):787-795.
47. Stein M, Keshav S, Harris N, Gordon S. Interleukin 4 potently enhances murine macrophage mannose receptor activity: a marker of alternative immunologic macrophage activation. J Exp Med. 1992; 176(1):287-292.
48. Fridlender ZG, Sun J, Kim S, et al. Polarization of tumor-associated neutrophil phenotype by TGF-beta: "N1" versus "N2" TAN. Cancer Cell. 2009;16(3):183-194.
49. Mantovani A. The yin-yang of tumorassociated neutrophils. Cancer Cell. 2009; 16(3):173-174.
50. Karp CL, Murray PJ. Non-canonical alternatives: what a macrophage is 4. J Exp Med. 2012;209(3): 427-431.
51. De Monte L, Reni M, Tassi E, et al. Intratumor T helper type 2 cell infiltrate correlates with cancerassociated fibroblast thymic stromal lymphopoietin production and reduced survival in pancreatic cancer. J Exp Med. 2011;208(3): 469-478.
52. Pedroza-Gonzalez A, Xu K, Wu TC, et al. Thymic stromal lymphopoietin fosters human breast tumor growth by promoting type 2 inflammation. J Exp Med. 2011;208(3):479-490.
53. Schmitt CA. Immunotherapy: TSLP fuels inflammation in breast and pancreatic tumors. Nat Rev Clin Oncol. 2011;8(5):254.